Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by LaserStock29on Apr 25, 2022 12:58pm
181 Views
Post# 34629429

RE:RE:RE:RE:RE:RE:RE:RE:BTD timeline...

RE:RE:RE:RE:RE:RE:RE:RE:BTD timeline...Again, the question to your subposition is has Theralase established open communication with FDA with it's Fast Track and got a Rolling Review.. so that the scenario you just outlined below is avoided.

Your subposition reads like TLT is sitting pouring coffee with a usb key waiting on a 'package of data' rather than having a Rolling review.

The data should already be presented to FDA on a Rolling Review.. any critical questions FDA has can be answered by TLT as they go along.. as it's understood trials have endpoints for individual patients as the months upcome. 

Any further talk on 'decision's here on this board is POINTLESS without Management Answering this question.

Yes I do really like Dr.Vera's addition.. 


ScienceFirst wrote:

TLT could, on its side, delay this, if it wanted to put all the chances on its side and add 12 more patients to the negative impact of the first 12 undosed, so they could present data on the first 37 patients.  That's an option they could give to themselves to ensure that the % of efficacy are to its advantage. 

But Eoganacht showed that even with the first 25, our chances are good as the % of efficacy still above competition.

It's an tough and important call as you only have one chance to make a good impression, so don't spoil it.



<< Previous
Bullboard Posts
Next >>